Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Osteosarcoma Osteosarcoma, which is most common in people 10 to 30 years of age, is
generally treated with resection and adjuvant chemotherapy. Detection of gene …

Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of
lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly …

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Anticancer immunotherapies involving the use of immune-checkpoint inhibitors or adoptive
cellular transfer have emerged as new therapeutic pillars within oncology. These treatments …

Harnessing an antitumor immune response has been a fundamental strategy in cancer
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …

We conducted a first-in-human study of intravenous delivery of a single dose of autologous T
cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a …